Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in SCN2A and SCN8A Epileptic Encephalopathies
Praxis Precision Medicines announced positive results from the EMBOLD study on relutrigine for SCN2A and SCN8A epileptic encephalopathies. The study was stopped early due to efficacy, and results will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025. Praxis plans to meet with the FDA to discuss the study results and potential NDA filing.
Praxis Precision Medicines Inc. has announced positive results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The study was stopped early following a recommendation by the Data Monitoring Committee due to demonstrated efficacy. Topline results from the EMBOLD study will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025. Praxis has confirmed an upcoming meeting with the FDA to discuss the study results and the potential path for a New Drug Application (NDA). The company will determine the timing for filing an NDA after this meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597168-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
